Biotech Stocks Facing FDA Decision In July 2019


Merck’s (MRK) New Drug Application for Relebactam in combination with *imipenem/cilastatin for the treatment of certain infections caused by certain susceptible Gram-negative bacteria in adults awaits the FDA decision on July 16, 2019.

*Imipenem/cilastatin, sold under the brand name Primaxin among others, is an antibiotic useful for the treatment of a number of bacterial infections.

Relebactam is an investigational, intravenous, class A and C beta-lactamase inhibitor, which carries both the tags - Qualified Infectious Disease Product (QIDP) designation and Fast Track status - granted by the FDA.

MRK closed Tuesday’s (June 25, 2019) trading at $85.24, down 0.32%.